Arthritis, Gouty
7
0
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
43%
3 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
The MAD Study of SSGJ-613 in Healthy Subjects
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
Celebrex In Acute Gouty Arthritis Study
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout